Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo …
M Castro, J Zangrilli, ME Wechsler… - The Lancet …, 2015 - thelancet.com
Background Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations.
Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts …
Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts …
[HTML][HTML] Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study
L Bjermer, C Lemiere, J Maspero, S Weiss, J Zangrilli… - Chest, 2016 - Elsevier
Background This phase 3 study further characterizes the efficacy and safety of reslizumab (a
humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma …
humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma …
[HTML][HTML] Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts
J Corren, S Weinstein, L Janka, J Zangrilli, M Garin - Chest, 2016 - Elsevier
Background IL-5, a mediator of eosinophil activity, is an important potential treatment target
in patients with uncontrolled asthma. The efficacy of reslizumab, a humanized anti-human IL-…
in patients with uncontrolled asthma. The efficacy of reslizumab, a humanized anti-human IL-…
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
…, ER Bleecker, A Menzies-Gow, JG Zangrilli… - The Lancet …, 2018 - thelancet.com
Background Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal
antibody that has been shown to significantly reduce asthma exacerbations and improve …
antibody that has been shown to significantly reduce asthma exacerbations and improve …
[HTML][HTML] The Ced-3/interleukin 1β converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2α are substrates for the apoptotic mediator CPP32
SM Srinivasula, T Fernandes-Alnemri, J Zangrilli… - Journal of Biological …, 1996 - ASBMB
Recent evidence suggests that CPP32 is an essential component of an aspartate-specific
cysteine protease (ASCP) cascade responsible for apoptosis execution in mammalian cells. …
cysteine protease (ASCP) cascade responsible for apoptosis execution in mammalian cells. …
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma …
…, A Burden, L McDermott, EG Gil, JG Zangrilli… - The lancet respiratory …, 2021 - thelancet.com
Background ANDHI was done to assess the efficacy of benralizumab, including onset of effect
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
…, M Goldman, P Newbold, JG Zangrilli - European …, 2018 - Eur Respiratory Soc
Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and
improves lung function for patients with severe, uncontrolled asthma with eosinophilic …
improves lung function for patients with severe, uncontrolled asthma with eosinophilic …
[HTML][HTML] Characterization of severe asthma worldwide: data from the International Severe Asthma Registry
…, M Hew, M Peters, ES Harvey, M Alacqua, J Zangrilli… - Chest, 2020 - Elsevier
Background Clinical characteristics of the international population with severe asthma are
unknown. Intercountry comparisons are hindered by variable data collection within regional …
unknown. Intercountry comparisons are hindered by variable data collection within regional …
[HTML][HTML] Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort
…, M Peters, C Taillé, C Taube, TN Tran, J Zangrilli… - Chest, 2021 - Elsevier
Background Phenotypic characteristics of patients with eosinophilic and noneosinophilic
asthma are not well characterized in global, real-life severe asthma cohorts. Research …
asthma are not well characterized in global, real-life severe asthma cohorts. Research …
[HTML][HTML] Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma
…, JM Fahrenholz, Y Shalit, M Garin, J Zangrilli… - The Journal of Allergy …, 2017 - Elsevier
Background In placebo-controlled trials, reslizumab, an anti-IL-5 monoclonal antibody,
significantly reduced asthma exacerbations and improved lung function and asthma control in …
significantly reduced asthma exacerbations and improved lung function and asthma control in …